drugset / Trial / NCT04902261
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy of Tislelizumab combined with Nab-paclitaxel and Gemcitabine in the treatment of recurrent pancreatic cancer
Timeline
- Start
- 2020-11-20
- Primary completion
- 2023-11-20
- Completion
- 2023-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |